Anesthesiologist Assistant in Maryland Medicare Details, Address, Contact
5 Anesthesiologist Assistant nurses found. Showing 1 - 5
 Ms. Joann B. Roberts, PA-AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 6800 Wilson Ln, Bethesda, MD 20817 Phone: 301-915-4255 |
Wintye Goitom, CRNA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 6400 Goldsboro Rd Ste 400, Bethesda, MD 20817 Phone: 301-263-0820 Fax: 301-263-0820 |
 John Clifton Campbell, CRNA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 7503 Surratts Road, Clinton, MD 20735 Phone: 301-870-7001 Fax: 301-870-6697 |
Ms. Mary Margaret Connors, CRNA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 1952a Pulaski Hwy, Edgewood, MD 21040 Phone: 410-538-7000 Fax: 410-679-7825 |
Mr. Ikenna Uzomah, CAA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 6202 43rd Ave, Hyattsville, MD 20781 Phone: 301-351-3800 |
News Archive
Biogen Idec 2010 total revenues increase 8% to $4.7 billion
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.
FDA updates Zelnorm labeling a treatment of women with irritable bowel syndrome
The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.
Chimerix commences first-in-human study of CMX157 for HIV
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
› Verified 6 days ago